Segment & Geographic Data Quant-Grade Normalized (live API) API & CSV Delivery

Aspira Women S Health Inc's Business Segments

Aspira Women S Health Inc's reported revenue by business segment and by geographic region, quarterly and annual, normalized against the consolidated income statement. Free below: the top 3 rows per table, this quarter and this fiscal year. Subscriber access adds the full segment history and operating income by segment.

Segment Data As of Q2 ((Jun 30 2026))

Reportable Segments

Per the company's own filing, this quarter

Largest Segment

Single reportable segment

23605.9% of revenue

Total Revenue

$ 0

Consolidated, this quarter

Regions Reported

Geographic regions, this quarter

API endpoints for this dataset

                        https://api.csimarket.com/api/v1/companies/AWHL/segments                    

                        https://api.csimarket.com/api/v1/companies/AWHL/geographic                    

                        https://api.csimarket.com/api/v1/companies/AWHL/exposure                    

Programmatic access for models, analytics, and integration workflows.

Pull these exact ratios programmatically

Get an API key License this feed for redistribution / AI →

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Revenue Share by Reportable Segment - Q2 ((Jun 30 2026))

Single reportable segment23605.9%

Revenue by Reportable Segment - Q2 ((Jun 30 2026))

Segment	Period	Revenue (Millions)	% of Total	Operating Income
Single reportable segment	Q2 ((Jun 30 2026))	$ 4	23605.9%	-

Description of Aspira Women S Health Inc

Aspira Women’s Health Inc. develops and commercializes noninvasive, AI-powered diagnostic tests for gynecologic diseases, with an initial focus on ovarian cancer. The company aims to extend its diagnostic tests to other gynecologic conditions that are challenging to assess noninvasively. Aspira markets its products through both direct and distributed channels and promotes the diagnostic benefits of its Ova1Plus test compared to cancer antigen 125 (CA-125) alone, particularly for women with adnexal masses across diverse racial groups. The company seeks to increase access to its tests for Medicaid patients and supports legislative and professional guideline adoption. Aspira owns Aspira Labs, a CLIA-certified laboratory located in Texas. Its product pipeline includes ENDOinform, a multi-marker test combining serum proteins, microRNA, and clinical data for endometriosis diagnosis, and OvaWatch, a monitoring tool for adnexal masses related to ovarian cancer. Additionally, Aspira is developing OVAinform, a multi-marker test to assess ovarian cancer risk, with plans to expand its use to asymptomatic women at elevated risk. The company utilizes AI-enabled assays and collaborates with research institutions to advance diagnostic accuracy by integrating multiple biomarkers for complex diseases such as cancer.